Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
NCT06765161Phase 3Recruiting
- Sponsor
- Clinique Neuro-Outaouais
- Start
- Feb 2025
- Primary completion
- Jan 2027
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
A Phase 3 trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by Clinique Neuro-Outaouais. Started Feb 2025; status: recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06765161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06765161.